anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This multi-site, multi-national project will evaluate the relative effectiveness of four therapy protocols for pharyngeal phase swallowing impairment in the stroke population. For this study, patients with chronic dysphagia secondary to stroke will be assigned to one of four treatment protocols. These four protocols differ in respect to the intensity of treatment and the inclusion of surface electromyography (SEMG) biofeedback as an adjunct to treatment. All patients will complete a total of 30 hours of therapy with data collection to assess progress at intervals of every 10 sessions. Treatment outcomes will be measured using a combination of physiologic and behavioral measures. Data derived from this study should contribute significantly to our understanding of the rehabilitative process in the neurogenic dysphagic population and will provide the foundation for the establishment of efficacious, cost-efficient patient services.
Concomitant use of benzodiazepines, including chlordiazepoxide and amitriptyline hydrochloride tablets, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. 

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe chlordiazepoxide and amitriptyline hydrochloride tablets concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of chlordiazepoxide and amitriptyline hydrochloride tablets than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking chlordiazepoxide and amitriptyline hydrochloride tablets, prescribe a lower initial dose of the opioid and titrate based upon clinical response.

Advise both patients and caregivers about the risks of respiratory depression and sedation when chlordiazepoxide and amitriptyline hydrochloride tablets are used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see PRECAUTIONS: Drug-Drug Interactions).
A method a'nd composition for treating open wounds. The method includes thorough cleaning of the wound, and application of the composition and a sterile dressing. The composition and dressing may be changed as needed. The composition is an aqueous solution of 90-110mg/mL glycosaminoglycan. Preferably, chondroitin sulfate will be used. Additional components, that may be added singly or in combination, include collagen, other glycosaminoglycans, glucosamine hydrochloride, glucosamine sulfate, certain buffering agents, and certain preservatives. Using the solution of this invention on acute or chronic open wounds aids the natural healing process, thereby increases the rate of healing.
One aspect of the disclosure describes a lipid conjugated cationic molecule. Other aspects of the disclosure describes nanoparticle delivery systems and methods of making the systems are disclosed. An embodiment of the nanoparticle delivery system has sustained gene delivery properties, the nanoparticle delivery system can be synthesized using biodegradable and biocompatible polymers via self-assembly. The nanoparticle delivery system comprises a plurality of nanoparticle depots, each of which has a particle-in-particle structure, and is composed of a polymeric nanoparticle, which encapsulates cationic molecule/nucleic acid complexes, facilitating enhanced retention and prolonged release of the gene payload. The polymeric nanoparticle comprises a shell, and a nanocomplex of the cationic molecule and a polynucleotide, the nanocomplexes are distributed within the shell and/or embedded in the shell. Another embodiment of the nanoparticle delivery system has one or more nanocomplexes. The one or more nanocomplexes includes a lipid conjugated cationic molecule and a polynucleotide.
The invention relates to an asarum heterotropoide extract of asarum as well as a preparation method and application of the extract, and particularly relates to an asarum heterotropoides extract of asarum. The extract comprises essential oil and a water extract, wherein the essential oil accounts for 2% by weight, and the water extract accounts for 98% by weight. The preparation method of the extract comprises the following steps: extracting essential oil in asarum heterotropoides roots and rhizomes by adopting a supercritical fluid extraction method; including the essential oil by cyclodextrin, and hermetically storing for later use; condensing, refluxing and extracting dregs by water; filtering by an aqueous extract, and drying to obtain powder; finally evenly mixing a beta-cyclodextrin inclusion compound with dry powder, so as to obtain the asarum heterotropoides extract, and hermetically storing. Application of the asarum heterotropoides extract in preparation of two oral appliances relates to a drug paste and an oral patch. The drug paste disclosed by the invention has the effects of preventing and treating odontalgia, gingivitis, periodontitis and dental ulcer. The oral patch has the efficacies of treating the dental ulcer, easing pain, diminishing inflammation and preventing gum bleeding.
This study aimed to evaluate the effects of general control non-derepressible 2 (GCN2) on osteoarthritis (OA) in vivo and in vitro. First, anterior cruciate ligament transection (ACLT)-induced rat model and interleukin (IL)-1β-induced ATDC5 chondrocyte were established. Hematoxylin and eosin staining and safranin O/fast green staining were employed for analyzing the histological changes in the rat cartilage. In addition, immunohistochemistry, quantitative real-time polymerase chain reaction, enzyme-linked immunosorbent assay, western blot, and immunofluorescence staining were employed for examining cartilage degeneration-, inflammation-, autophagy-, and NLR family pyrin domain containing 3 (NLRP3) inflammasome-associated genes expression. Moreover, 2,7-dichlorodihydrofluorescein acetoacetic acid probe was utilized for examining the intracellular reactive oxygen species. In addition, 5-ethynyl-2'-deoxyuridine assay and flow cytometry were applied for detecting chondrocyte proliferation and apoptosis IL-1β-treated ATDC5 chondrocytes. GCN2 overexpression ameliorated articular cartilage degeneration and inflammation but promoted chondrocyte autophagy in ACLT-induced OA rats. Similarly, we demonstrated that the upregulation of GCN2 could promote chondrocyte proliferation, suppress chondrocyte apoptosis, attenuate chondrocyte inflammation and extracellular matrix degradation, and promote chondrocyte autophagy. Moreover, GCN2 overexpression could inhibit the activation of NLRP3 inflammasome in IL-1β-induced ATDC5 chondrocyte. Furthermore, 3-methyladenine neutralized the protective and autophagy-promoting effects of GCN2 overexpression on ATDC5 chondrocytes. GCN2 could attenuate inflammation and cartilage degeneration, promote chondrocyte autophagy, and inhibit NLRP3 inflammasome activation in OA.
PROBLEM TO BE SOLVED: To provide a Chinese-medicine composition having lipid-lowering and liver-protecting effects, and preparing method and application thereof.SOLUTION: Provided is a compositus formulation constructed from Chinese medicine composition and medicinal additives. When calculating based on the number of pt.wt.s, according to a prescription of the Chinese medicine composition having lipid-lowering and liver-protecting effects, 60-120 parts of Gynura divaricata (L.) DC. subsp. formosana (Kitam.) F.G.Davies, 50-110 parts of pueraria roots, and 20-60 parts of Paeonia lactiflora Pall. are contained. A drug efficacy of the formulation is enhanced more remarkably, and it becomes more easily to take by constructing an effective prescription drug which can reduce lipid and protect liver based on a traditional Chinese pharmacology theory and by making a contemporary formulation, such as a capsule, through contemporary pharmaceutical means. The formulation has a role of reducing lipid and protecting liver. Thus it can be used for prevention or treatment of disorders, such as hyperlipidemia, obesity, hepatitis viral, drug induced hepatic injury, and hepatopathy alcoholic.
The invention discloses a Chinese traditional medical prescription for curing scald and a preparing method thereof. The prescription is prepared by the raw materials with weight proportions of: 5 to 40 percent of soyabean coat, 10 to 30 percent of mercury sulphide, 0.5 to 5 percent of borneol and 50 to 85 percent of benne oil. The raw materials of the Chinese traditional medical prescription are easily available. The invention has the advantages of simple production technique, low cost and distinct effect and has the functions of diminish inflammation, killing pain, refreshing skin and regenerating muscle, etc. The pain fades after the medicine is used for 1 to 2 minutes. Complete heal is generally realizable in one week without scar.
Three or six patients will be treated with the dose of 0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan. DLT will be observed within 28 days after administration.
In a new procedure for the conversion of an antiinflammatory steroid which undergoes crystal growth in chlorofluorinated aerosol propellants into a crystalline form which is not susceptible to this crystal growth, the steroid is crystallised from ethyl acetate and the prod. obtd. is micronised. New antiinflammatory steroid aerosol preparations contain a steroid which has been subjected to the above procedure. The new procedure prevents steroid crystal growth to a size (>20 mu) unsuitable for administration by inhalation. The procedure is simple, proceeds in almost 100% yield, and avoids the use of toxic materials (ethyl acetate has a rat LD50 of 11.3 g/kg. p.o., and gives no toxic effects when administered to rats and mice in a dosage of 1 g/kg. for 30 days.
BACKGROUND: Gallstones are strongly associated with eating occasion (EO) and energy distribution, but few studies have addressed this aspect. Therefore, we utilize the data from 2017 to 2018 National Health and Nutrition Examination Survey (NHANES) to explore the association between temporal eating patterns and energy distribution patterns with the incidence of gallstones.
METHODS: Our study comprised participants who completed the NHANES dietary intake interview and self-reported health questionnaire at age 20 or older. The self-report method for gallstones (have you ever been told by a doctor) was used. We use the latent class analysis (LCA) identified temporal eating patterns, and identified energy distribution patterns through latent profile analysis (LPA). The association between temporal eating patterns, energy distribution patterns, and gallstones was examined using logistic regression modeling.
RESULTS: The study included a total of 4,692 participants. LCA identified four temporal eating patterns labeled as "Conventional," "Early breakfast," "Later breakfast," and "Grazing." Compared to the "Conventional" pattern, the "Early breakfast" pattern (OR 0.809, 95%CI 0.808-0.811) was associated with a reduced risk of gallstones, while the "Later breakfast" (OR 1.435, 95%CI 1.432-1.438) and "Grazing" (OR 1.147, 95%CI 1.145-1.148) patterns were associated with an increased risk of gallstones. LPA identified four energy distribution patterns labeled as "Guideline," "High carbohydrates," "Carbs-fat balance," and "High fat." The "High carbohydrates" pattern (OR 1.329, 95%CI 1.326-1.331) was associated with an increased risk of gallstones compared to the "Guideline" pattern. The "Carbs-fat balance" pattern (OR 0.877, 95%CI 0.876-0.879) and the "High fat" pattern (OR 0.848, 95%CI 0.846-0.850) were significantly and negatively associated with the risk of gallstones.
CONCLUSIONS: To summarize, inappropriate timing of eating and energy sources are associated with gallstones. As a dietary prevention measure for gallstones, we suggest adhering to a regular eating routine and avoiding overly casual and frequent food consumption. If the main EO routine occurs in the morning, this time should not exceed 9:00 a.m. Additionally, reducing carbohydrate intake and maintaining a moderate level of fat intake is believed to contribute to a lower risk of gallstones.
The pulsatile release of GnRH stimulates the synthesis and secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The frequency of LH pulses in the mid and late follicular phase is approximately 1 pulse per hour. These pulses can be detected as transient rises in serum LH. At midcycle, a large increase in GnRH release results in an LH surge. The midcycle LH surge initiates several physiologic actions including: ovulation, resumption of meiosis in the oocyte, and luteinization. Luteinization results in a rise in serum progesterone with an accompanying decrease in estradiol levels.

Ganirelix Acetate acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway. It induces a rapid, reversible suppression of gonadotropin secretion. The suppression of pituitary LH secretion by Ganirelix Acetate is more pronounced than that of FSH. An initial release of endogenous gonadotropins has not been detected with Ganirelix Acetate, which is consistent with an antagonist effect. Upon discontinuation of Ganirelix Acetate, pituitary LH and FSH levels are fully recovered within 48 hours.
Clinical research in blood stem cell and bone marrow transplantation documents improvements in disease free intervals, disease free survival, and the severity of treatment related toxicities. However, it is important for patients and families to know the quality of life (QOL) they can expect following an allogeneic transplant. In this longitudinal study we will compare the QOL of patients undergoing a non-myeloablative allogeneic peripheral blood stem cell transplant (A-PBSCT) prospectively with that of a myeloablative A-PBSCT. Subjects (n=106) over the age of 18 will be enrolled. Measures of quality of life (Medical Outcomes Study Short Form-MOS SF-36 and Functional Assessment of Cancer Therapy-General and Bone Marrow Transplant - FACT-G and FACT-G/BMT) and symptom distress (Symptom Distress Scale - SDS) will be administered prior to transplant (baseline) and at set interval post transplant. Data will be analyzed using repeated measures analysis of variance and regression analysis.
The present invention relates to a medicinal compound for treating the anorectal cancer, and a preparing method thereof. The medicinal compound comprises carboplatin, tegafur, atropine, sanqi, Yunnan Baiyao, norfloxacin and polyethylene glycol. During preparation, the polyethylene glycol is heated on a water bath so as to be melted, and then the temperature of the polyethylene glycol is reduced; other medicines are added into the polyethylene glycol, and then, the medicinal compound is prepared according to a suppository thermal melting method. The medicinal compound used for treating the anorectal cancer is specifically suitable for patients suffering from anal pipe cancer, rectal cancer and colon cancer and has the advantages of good mucosa absorption, strong tissue permeation, good anti-cancer effect and the functions of hemostasis and spasmolysis pain relief. The medicinal compound is dosed by means of anus intervention; thus, the decomposition and the damage of an enteron acid base and multiple digestive enzymes to the medicinal compound when the medicinal compound is orally taken are avoided, and toxic action to the organs of the whole body by adopting a vein dosing mode is also avoided. The medicinal compound is absorbed by anorectal mucosa and acts directly on tumor tissues; the medicinal compound has the advantages of high local concentration, good therapeutic effect, convenient use, economy and high reliability.
Pre- or perimenopausal women and all men are treated with tamoxifen together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
Nausea and vomiting are common symptoms that can reduce quality of life and indicate life-threatening illness. Acute nausea and vomiting last up to 7 days. In the absence of alarm symptoms, they are typically treated symptomatically and without an extensive evaluation. Typical causes include gastroenteritis or other viral syndromes, foodborne illness, acute migraine headaches, vestibular disturbances, early pregnancy, and adverse effects of medication. Chronic nausea and vomiting last 4 weeks or longer and have a broad differential diagnosis. Causes can be gastrointestinal, infectious, metabolic, neurologic, psychiatric, or related to medications and toxins. A careful history of related factors is essential to guide the initial evaluation and narrow the differential diagnosis. These factors include associated symptoms, timing of onset and duration of symptoms, exacerbating or relieving factors, alarm symptoms, medication and substance use, relationship with recent food ingestion, and comorbidities. Nonpharmacologic management options include fluid and electrolyte replacement; small, frequent meals; and avoidance of trigger foods. Antiemetic drugs effectively reduce symptoms of acute nausea and vomiting, but chronic symptoms are often more challenging to treat. When a specific etiology is not identified, a serotonin antagonist or dopamine antagonist can be used. However, medications may also target the suspected cause of symptoms and the neurotransmitters involved in central and peripheral pathways of nausea and vomiting. Pharmacologic therapy should be used for the shortest time necessary to control symptoms.
The present invention provides a powder spraying agent for relieving inflammation on mucous membranes. The present invention has the content medicine of yunnan baiyao with the hemostasis function and the antiphlogosis function. The present invention is characterized in that each spraying agent has 0.01 to 0.2g of yunnan baiyao extracts and auxiliary materials (with high biological mucous membrane compatibility and film forming capability) as the rest; the materials are made into the spraying agent which is acceptable in medicine. The present invention has the comprehensive functions of resisting bacteria, stopping bleeding, alleviating pain, relieving inflammation, improving the microcirculation, etc., and has other effects of fast stopping mucous membrane bleeding, relieving mucous membrane inflammation, promoting the mucous membrane concrescence and avoiding the scar generation. After sprayed on the mucous membranes, the powder spraying agent absorbs partial moisture, is dispersed to form a layer of protective film, and assists the mucous membrane recovery in the mucous membrane repairing process. The products of the present invention have the advantages of convenient use, stable performance and no stimulation.
PURPOSE: The aim of this study was to analyze changes in corneal biomechanical properties after implantation of intracorneal ring segments (ICRSs) in keratectasia.
METHODS: This retrospective single-center study included 112 patient eyes that underwent femtosecond laser-assisted ICRS implantation (Intacs SK; Addition Technology Inc, Des Plaines, IL) for keratectasia. Biomechanical analysis was performed using the Ocular Response Analyzer (ORA; Reichert Inc, Depew, NY), with determination of corneal resistance factor, corneal hysteresis, and Keratoconus Match Index, as well as by Corvis ST (OCULUS, Wetzlar, Germany), with determination of stiffness parameter A1, Ambrosio relational thickness to the horizontal profile (Arth), integrated radius, deformation amplitude ratio, and stress-strain index as well as Corvis Biomechanical Index and Tomographic Biomechanical Index. Data collection was performed preoperatively and 6 months postoperatively for ORA and Corvis ST and additionally after 1 and 2 years for ORA.
RESULTS: The corneal resistance factor decreased significantly postoperatively (5.8 ± 1.7 mm Hg) compared with preoperatively (6.75 ± 3.7 mm Hg; P = 0.021) and increased again during follow-up (6.2 ± 1.9 mm Hg; P = 0.024), without regaining preoperative values. Corneal hysteresis and Keratoconus Match Index did not change significantly. Stiffness parameter A1 ( P = 0.045) increased significantly after ICRS implantation and Arth decreased significantly from 181 ± 85 to 150 ± 92 ( P = 0.016). However, there was no significant postoperative change for others Corvis parameters.
CONCLUSIONS: Corneal biomechanical properties showed inconsistent changes after ICRS implantation. Classical corneal biomechanical parameters (using single central air-puff tonometers) do not seem to be suitable for follow-up after ICRS implantation.
PURPOSE:To provide a method for producing an extract or extract powder of a mycelium of Ganoderma lucidum Karst. in which the destruction of pharmacodynamically effective and nutritious ingredients such as vitamins or minerals contained in the mycelium of the Ganoderma lucidum Karst. can be reduced and the production means is extremely simple. CONSTITUTION:This method for producing extract powder of a mycelium of Ganoderma lucidum Karst. is to inoculate Ganoderma lucidum Karst. into a solid culture medium using chaff as a raw material, proliferate the mycelium of the Ganoderma lucidum Karst., simultaneously untye a bunch of a solid culture medium containing the mycelium of the Ganoderma lucidum Karst., add warm water at 50-55 deg.C thereto, stir the resultant mixture, further add a cellulolytic agent, stir the prepared mixture, further filter the dissolved mycelium of the Ganoderma lucidum Karst., provide an extract thereof, then add beta- cyclodextrin in the resultant extract separated from the mycelium of the Ganoderma lucidum Karst., mix and stir the prepared mixture, dry the obtained mixture in a vacuum freezing dryer, pulverize and powder the dried mixture.
PURPOSE:To provide a new compound useful for readily producing an amino- substituted spiro compound as an intermediate for synthesis of an antimicrobial compound useful as a medicine. CONSTITUTION:A compound of formula I (R<1> is a benzyl composed of phenyl which may be substituted with a halogen, etc., and methylene, t-butyl, etc.; R<2> is phenyl which may be substituted with a halogen, nitro, etc., a 1 to 6C alkyl, etc.), e.g. 1-benzyloxyacetyl-1-methoxycarbonylcyclopropane. The compound of formula I is obtained, e.g. by reacting a alpha-alkyloxy-beta-ketoester derivative with a compound of formula II (XA and XB are each an atom or a functional group respectively eliminable by a nucleophilic reaction) in a solvent under a basic condition. In addition, a compound of formula VI can be obtained by reducing a compound of formula I in the presence of a metal hydride complex, reacting the resultant compound of formula III with a substitute sulfonyl chloride in a solvent under a basic condition and reacting the obtained compound of formula IV with a compound of formula V (Q is phenyl which may be substituted with a halogen, etc.).